Provided by Tiger Trade Technology Pte. Ltd.

Ocular Therapeutix

10.80
+0.22502.13%
Volume:932.91K
Turnover:10.00M
Market Cap:2.36B
PE:-7.63
High:11.01
Open:10.58
Low:10.47
Close:10.57
52wk High:16.44
52wk Low:6.23
Shares:218.91M
Float Shares:185.00M
Volume Ratio:1.43
T/O Rate:0.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4140
EPS(LYR):-1.4203
ROE:-72.99%
ROA:-34.95%
PB:4.54
PE(LYR):-7.60

Loading ...

Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says

MT Newswires Live
·
May 07

Ocular Therapeutix Price Target Maintained With a $30.00/Share by RBC Capital

Dow Jones
·
May 06

Ocular Therapeutix (OCUL) Gets a Buy from Chardan Capital

TIPRANKS
·
May 06

Analyst Reiterates Buy Rating on OCUL, Keeps Axpaxli-Driven Price Target Unchanged at $18

TIPRANKS
·
May 06

Stock Track | Ocular Therapeutix Plummets 6.86% Intraday After Q1 Earnings Miss Estimates

Stock Track
·
May 06

Stock Track | Ocular Therapeutix Plunges 6.45% in Pre-Market After Q1 Earnings Miss Estimates

Stock Track
·
May 05

Ocular Therapeutix reports Q1 EPS (40c), consensus (31c)

TIPRANKS
·
May 05

Earnings Flash (OCUL) Ocular Therapeutix Posts Q1 Loss $0.40 a Share, vs. FactSet Est of $0.31 Loss

MT Newswires Live
·
May 05

Ocular Therapeutix Q1 EPS $(0.40) Misses $(0.33) Estimate, Sales $10.785M Miss $12.599M Estimate

Benzinga Earnings
·
May 05

Ocular Therapeutix Inc - Cash and Cash Equivalents of $666.7 Mln as of March 31, 2026,Expected Runway Into 2028

THOMSON REUTERS
·
May 05

Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

GlobeNewswire
·
May 05

What Ocular Therapeutix (OCUL)'s SOL-X Long-Term AXPAXLI Extension Study Means For Shareholders

Simply Wall St.
·
May 02

Ocular Therapeutix announces annual shareholder meeting

Reuters
·
May 01

Ocular Therapeutix (OCUL) Receives a Buy from William Blair

TIPRANKS
·
Apr 29

Ocular Therapeutix enrolls first patient in Axpali trial

TIPRANKS
·
Apr 29

Ocular Therapeutix enrolls first patient in SOL-X AXPAXLI wet AMD extension trial

Reuters
·
Apr 29

Ocular Therapeutix™ Announces First Patient Enrolled in Sol-X Long-Term Extension Trial for Axpaxli™ in Wet Amd

THOMSON REUTERS
·
Apr 29

Ocular Therapeutix to report first-quarter results, host conference call and webcast

Reuters
·
Apr 28

Ocular Therapeutix to present at Bank of America Health Care Conference fireside chat

Reuters
·
Apr 27

Assessing Ocular Therapeutix (OCUL) Valuation As AXPAXLI Prospects Drive A Wide Gap To Fair Value Estimates

Simply Wall St.
·
Apr 22